Ustekinumab: “Real-world” outcomes and potential predictors of nonresponse in treatment-refractory Crohn’s disease

BACKGROUND: Ustekinumab was approved in Europe for the treatment of adults with moderate to severe Crohn's disease (CD) in 2016, and there is an urgent need for data on its everyday use. AIM: To obtain data on the daily use of ustekinumab. METHODS: This is a retrospective monocentric study. Pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffmann, Peter, Krisam, Johannes, Wehling, Cyrill, Kloeters-Plachky, Petra, Leopold, Yvonne, Belling, Nina, Gauss, Annika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Retrospective Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710179/
https://www.ncbi.nlm.nih.gov/pubmed/31496626
http://dx.doi.org/10.3748/wjg.v25.i31.4481

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710179/
https://www.ncbi.nlm.nih.gov/pubmed/31496626
http://dx.doi.org/10.3748/wjg.v25.i31.4481

Ejemplares similares